TL;DR: The primary objective of LEAP was to provide patients with pre-approval access to lapatinib in combination with capecitabine in 42 countries.
Abstract: 1111 Background: LEAP is an expanded access study of lapatinib in combination with capecitabine in 42 countries. The primary objective of LEAP was to provide patients with pre-approval access to la...